Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy
Eye · 2024-11 · 38 (16) · 3059-3064
DOI: 10.1038/s41433-024-03218-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eye, online erschienen am 04.07.2024. Verfasst von Christine Goodchild und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. christine_siew88@yahoo.com. Hauptthemen laut MEDLINE: Visual Acuity, Angiogenesis Inhibitors, Intravitreal Injections, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Age-related macular degeneration (AMD) remains a primary cause of blindness, with neovascular AMD (nAMD) presenting particular treatment challenges. Despite anti-vascular endothelial growth factor (anti-VEGF) therapies, many patients exhibit a suboptimal response to the previously available anti-vascular endothelial growth factor (anti-VEGF) therapies. This study evaluates the efficacy and treatment interval extension of faricimab in this patient cohort. METHODS: In a retrospective single-centre study at University Hospitals of Bristol and Weston, UK, nAMD patients suboptimally responsive to previous anti-VEGF therapies were switched to faricimab. Treatment started with an initiation phase of 4 monthly injections followed by a 'Treat and Extend' protocol. Outcomes included best-recorded visual acuity (BRVA), central subfield thickness (CST), the presence of retinal fluid, and treatment intervals. RESULTS: Among 98 eyes of 79 patients, following faricimab treatment, significant reductions in CST and retinal fluid were noted, indicating decreased disease activity. While BRVA changes were not statistically significant, the anatomical improvements suggest a potential therapeutic benefit. Notably, 40% of patients achieved extended treatment intervals, reducing the treatment burden. CONCLUSION: Faricimab offers a promising alternative for nAMD patients with suboptimal responses to prior anti-VEGF treatments, demonstrating significant anatomical improvements and the possibility of extended dosing intervals. These findings highlight the need for prospective real-world studies to further assess faricimab's role in nAMD management and its long-term impact on patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. christine_siew88@yahoo.com.
- Royal Victoria Eye and Ear Hospital, Adelaide Road, Dublin, Ireland. christine_siew88@yahoo.com.
- Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
- Department of Medicine, University of Bristol, Bristol, UK.
Zitieren
APA
Goodchild, C., Bailey, C., Soto Hernaez, J., Ahmed, E., & Salvatore, S. (2024). Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye, 38(16), 3059-3064. https://doi.org/10.1038/s41433-024-03218-7
Vancouver
Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye. 2024;38(16):3059-3064. doi:10.1038/s41433-024-03218-7
BibTeX
@article{Goodchild2024,
author = {Goodchild, Christine and Bailey, Clare and Soto Hernaez, Jimena and Ahmed, Eslam and Salvatore, Serena},
title = {Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy},
journal = {Eye},
year = {2024},
volume = {38},
number = {16},
pages = {3059--3064},
doi = {10.1038/s41433-024-03218-7}
}
EUVIMED